KAT/3BP: A Metabolism-Targeting Agent with Single and Combination Activity in Aggressive B-Cell Lymphomas
Our findings highlight the potential of KAT/3BP as a novel therapeutic option, either as a single agent or in combination regimens, for treating lymphomas.
Authors
- Alberto J. Arribas (ORCID: https://orcid.org/0000-0003-3123-6203)
- Luciano Cascione (ORCID: https://orcid.org/0000-0002-4606-0637)
- Elisa Civanelli (ORCID: https://orcid.org/0000-0001-5427-8372)
- Filippo Spriano (ORCID: https://orcid.org/0000-0002-8615-1568)
- Eleonora Cannas (ORCID: https://orcid.org/0009-0000-9551-7122)
- Anastasios Stathis (ORCID: https://orcid.org/0000-0002-2859-7529)
- Chiara Tarantelli (ORCID: https://orcid.org/0000-0002-4394-7742)
- Giorgia Risi
- Francesco Bertoni (ORCID: https://orcid.org/0000-0001-5637-8983)
- Luca Aresu (ORCID: https://orcid.org/0000-0002-7893-1740)
- Omar Kayali (ORCID: https://orcid.org/0000-0002-6642-2463)
- Young Hee Ko
Institutions
- SIB Swiss Institute of Bioinformatics (CH)
- Ente Ospedaliero Cantonale (CH)
- Institute of Oncology Research (CH)
- Columbus Center (US)
- University of Turin (IT)
- Università della Svizzera italiana (CH)
Publication Details
- Journal
- Cancers
- Published
- 2025-06-18
- DOI
- https://doi.org/10.3390/cancers17122034
- Citations
- 1
- Primary Topic
- Lymphoma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 1.47
Funders
- National Science Foundation
- Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung
- Swiss Cancer Research Foundation